Fasting Glucose vs Fasting Insulin: Which Blood Test Reveals More About Your Metabolic Health?

Every year, millions of people receive a routine blood panel. Their fasting glucose comes back at 94 or 96 mg/dL. Their doctor marks the result normal, tells them to keep up the good work, and moves on. Ten years later, the same patient has a fasting glucose of 126 mg/dL and a new diagnosis of type 2 diabetes. Nobody caught anything. Nobody was looking.

The problem is not the glucose reading. Glucose is an accurate measure of what it measures: circulating blood sugar at a single point in time, after a fast. The problem is that glucose is a lagging indicator. By the time it climbs out of the normal range, the metabolic damage has been accumulating for years, sometimes decades. The beta cells of the pancreas, which produce insulin, lose roughly half of their functional reserve before fasting glucose rises. The system fails quietly and completely invisibly inside a normal reference range.

Fasting insulin tells a different story. It measures the signal the body is sending, not the downstream outcome. When cells begin to resist insulin, the pancreas compensates by producing more of it. For a long time, that compensation works. Glucose stays normal. Nothing appears wrong. But the insulin level records the effort, the strain, the compensation. It is the equivalent of checking whether an engine is running hot rather than waiting for the oil light to come on.

Understanding the distinction between these two tests, what they measure, what they miss, and how to interpret them together, is one of the most practically valuable things you can do for your long-term metabolic health. This article walks through the science and the clinical application, so you can have a better conversation with your doctor or order the right tests yourself.

For a broader look at the full spectrum of metabolic biomarkers worth tracking, see our metabolic health guide, which covers how glucose, insulin, lipids, and inflammatory markers interact across the full metabolic picture.

Why Fasting Glucose Alone Is Not Enough

Fasting glucose became the primary metabolic screening tool because it is cheap, reproducible, and directly tied to the diagnostic criteria for diabetes. A fasting glucose below 100 mg/dL is classified as normal. Between 100 and 125 mg/dL is prediabetes. At 126 mg/dL or above on two separate occasions, the diagnosis is type 2 diabetes. These thresholds are well-validated for their intended purpose: identifying people who already have significantly impaired glucose metabolism.

But the thresholds were not designed to detect early insulin resistance. They were designed to define diabetes. That distinction matters enormously in practice, because the two are separated by a decade or more of physiological deterioration that fasting glucose will not detect.

Consider a concrete example. A person with a fasting glucose of 95 mg/dL sits firmly in the normal range, which is technically accurate: their blood sugar, after a 12-hour fast, is normal. But suppose that same person has a fasting insulin of 18 uIU/mL. To maintain that normal glucose, their pancreas is producing three to four times more insulin than it should. The reason the glucose is normal is not that the metabolic system is functioning well; it is that the pancreas is compensating aggressively. That compensation is the definition of insulin resistance, and it is invisible to a glucose-only panel.

A landmark paper by Tabak and colleagues published in The Lancet in 2009 mapped the trajectory of glucose, insulin sensitivity, and insulin secretion in the years before a type 2 diabetes diagnosis in a cohort of 6,538 civil servants. Their data showed that insulin resistance and compensatory hyperinsulinaemia precede the rise in fasting glucose by as much as thirteen years. The glucose begins to rise only in the final two to three years before diagnosis, as beta-cell reserve is finally exhausted. Everything before that point is a normal glucose reading sitting on top of a deteriorating system.

The Compensatory Hyperinsulinaemia Window

The period of normal glucose with elevated insulin is the most clinically important window in metabolic disease. It is the phase during which intervention is most effective and complications are most preventable. It is also the phase that standard metabolic panels almost universally ignore.

When peripheral tissues, primarily skeletal muscle, liver, and adipose tissue, begin to resist the action of insulin, the pancreatic beta cells respond by secreting more insulin. This is a functional adaptation: by raising the insulin signal, the body can still achieve adequate glucose uptake despite reduced sensitivity to that signal. For a period that can span a decade or more, this compensation is effective enough to maintain fasting glucose in the normal range.

The problem is that chronically elevated insulin is not benign. High insulin drives fat storage, promotes inflammation, increases androgen production in women with polycystic ovary syndrome, stimulates cell proliferation pathways implicated in certain cancers, and progressively worsens the very insulin resistance it is trying to compensate for. The pancreas is running at maximum effort, and that effort is causing downstream damage even while it keeps glucose looking normal.

Fasting glucose eventually rises only when beta-cell reserve is depleted below approximately 50% of baseline function. By that point, the compensatory window has closed. What remained was an opportunity to reverse the insulin resistance through dietary change, exercise, and other interventions before irreversible beta-cell loss occurred. That window is identified reliably only by fasting insulin testing.

For a detailed explanation of the cellular mechanisms underlying insulin resistance and why beta cells fail progressively, see our full insulin resistance explainer, which covers the molecular biology alongside the clinical implications.

Fasting Insulin: Reference Ranges vs Optimal Values

Here is where the clinical picture becomes particularly important to understand. Standard laboratory reference ranges for fasting insulin typically flag results as abnormal only above 24 to 25 uIU/mL, depending on the laboratory. This threshold was set to capture overt hyperinsulinaemia, not to identify optimal metabolic function.

The most consequential research on this question comes from Dr. Joseph Kraft, a pathologist who between 1965 and 1975 performed five-hour oral glucose tolerance tests with simultaneous insulin measurements on 14,384 patients at St. Joseph Hospital in Chicago. His data, published in Laboratory Medicine in 1975, revealed that 75% of patients with normal fasting glucose had demonstrably abnormal insulin response curves. Kraft identified five distinct insulin response patterns, only one of which he considered normal, and used insulin curve patterns to predict cardiovascular disease risk years before standard glucose testing would detect any abnormality. His conclusion, largely ignored by mainstream endocrinology for decades, was that cardiovascular disease is a late-stage complication of diabetes in situ: insulin resistance detected by insulin curves, not glucose.

Based on Kraft's data and subsequent longevity cohort research, optimal fasting insulin is considered to be below 5 uIU/mL. A result between 5 and 10 uIU/mL is acceptable but indicates some degree of insulin resistance that warrants lifestyle attention. A result between 10 and 15 uIU/mL is concerning and represents early to moderate insulin resistance. A result above 15 uIU/mL with a normal fasting glucose represents severe undetected insulin resistance that would pass completely unnoticed on a standard metabolic panel.

The gap between the standard laboratory cutoff of 25 uIU/mL and the optimal value of below 5 uIU/mL is not a rounding error. It represents a fivefold difference in what is considered acceptable versus what the evidence suggests is associated with long-term metabolic health. A result of 18 uIU/mL, which most standard labs would report without comment, represents a level of insulin compensation that, sustained over years, carries meaningful cardiovascular and metabolic risk.

HOMA-IR: The Combined Score That Quantifies Resistance

Fasting insulin in isolation is informative. Combined with fasting glucose in the HOMA-IR calculation, it becomes a validated quantitative measure of insulin resistance that has been used in thousands of research studies and clinical settings worldwide.

HOMA-IR stands for Homeostasis Model Assessment of Insulin Resistance. The formula was published by Matthews and colleagues in Diabetologia in 1985 and has since been validated against gold-standard euglycaemic hyperinsulinaemic clamp measurements in multiple populations. Using US units, the calculation is straightforward: multiply fasting glucose in mg/dL by fasting insulin in uIU/mL, then divide by 405. Using SI units, multiply fasting glucose in mmol/L by fasting insulin in uIU/mL, then divide by 22.5.

The resulting score has well-established interpretation thresholds. A HOMA-IR below 1.0 is optimal. Between 1.0 and 2.5 is borderline and warrants monitoring. Above 2.5 is consistent with insulin resistance. Above 3.5 indicates significant resistance. The San Antonio Heart Study and multiple other large population cohorts have validated these cutoffs against clinical outcomes including cardiovascular events, progression to type 2 diabetes, and all-cause mortality.

To see how HOMA-IR sits within the broader framework of biomarker interpretation, our optimal blood test ranges guide provides context for how these numbers relate to other key metabolic and inflammatory markers.

The power of HOMA-IR lies in exactly the scenario described above: a person with fasting glucose of 95 mg/dL and fasting insulin of 18 uIU/mL has a HOMA-IR of (95 x 18) / 405 = 4.2. That score immediately identifies significant insulin resistance despite a textbook-normal glucose reading. Without the insulin measurement, that number would never be calculated, and the dysfunction would remain invisible.

Large-Scale Evidence: What Population Studies Show

Kraft's 1975 data was compelling but came from a single institutional dataset. Subsequent large-scale epidemiological research has consistently reinforced the predictive value of fasting insulin independent of fasting glucose.

The Nurses Health Study, a cohort of over 120,000 US female registered nurses followed for decades, generated a landmark 2001 analysis by Hu and colleagues published in the New England Journal of Medicine. While that paper focused on diet and lifestyle as risk factors for type 2 diabetes, its data confirmed that elevated fasting insulin is an independent predictor of both type 2 diabetes and cardiovascular disease, even when fasting glucose remains in the normal range. Women who developed diabetes showed elevated insulin years before their glucose crossed diagnostic thresholds.

McLaughlin and colleagues, publishing in Annals of Internal Medicine in 2003, examined overweight individuals and found that the triglyceride-to-HDL cholesterol ratio was a particularly strong indirect marker of insulin resistance, correlating closely with direct measures. A triglyceride-to-HDL ratio above 3.0 (in mg/dL units) in an overweight person predicts insulin resistance with clinically meaningful sensitivity. This matters because triglyceride and HDL are universally included in standard lipid panels, meaning a simple ratio calculation on data many patients already have can serve as a preliminary screening tool before fasting insulin is ordered.

The Tabak Lancet 2009 analysis mentioned earlier remains one of the most visually striking demonstrations of the timeline: glucose and insulin sensitivity curves in the pre-diagnosis period show a long plateau of stable glucose sitting on top of rising insulin and falling insulin sensitivity, followed by a sharp late-stage decline in beta-cell function and corresponding glucose rise. The entire early phase is clinically silent on glucose testing alone.

How to Order Both Tests and Interpret the Results

Ordering fasting glucose is straightforward: it is included in the basic metabolic panel (BMP) and comprehensive metabolic panel (CMP), both of which are routinely ordered in primary care. Ordering fasting insulin requires a specific request.

Many general practitioners will order fasting insulin if asked directly and if a clinical rationale is provided, such as family history of type 2 diabetes, metabolic syndrome features, or unexplained weight gain. However, insurance coverage is inconsistent, and some physicians unfamiliar with functional medicine testing may decline. In those cases, direct-access laboratory services such as Lets Get Checked, Own Your Labs, Ulta Lab Tests, and similar platforms allow patients to order fasting insulin independently without a physician referral, at relatively low cost.

Proper fasting protocol is important for accurate results. Both fasting glucose and fasting insulin require a 12-hour fast before blood draw. Water is permitted. Avoid exercise the morning of the test, as acute exercise temporarily lowers both glucose and insulin through non-insulin-mediated glucose uptake in muscle. Do not test during acute illness or significant psychological stress, both of which activate cortisol and can transiently elevate glucose and insulin.

Once results are in hand, interpret them in combination. Fasting glucose in the optimal range below 85 mg/dL with fasting insulin below 5 uIU/mL and HOMA-IR below 1.0 represents excellent metabolic function. Normal glucose with elevated insulin (10 or above) indicates the compensatory window: the system is maintaining glucose at the cost of high insulin output. Elevated glucose with elevated insulin suggests advanced insulin resistance with early beta-cell stress. Elevated glucose with low insulin suggests significant beta-cell loss, which may indicate later-stage type 2 diabetes or type 1 diabetes and warrants urgent clinical attention.

Complementary Tests: Building a Full Metabolic Picture

Fasting glucose and fasting insulin, combined as HOMA-IR, are the foundation of early metabolic screening. Several additional markers meaningfully extend the picture.

HbA1c (glycated haemoglobin) reflects average glucose over the preceding two to three months and is useful for tracking progression over time. However, it is insensitive for early insulin resistance: HbA1c typically remains in the normal range until glucose has been chronically elevated for an extended period. It is a progression marker, not an early detection tool. Optimal HbA1c is below 5.3%; the normal reference range extends to 5.7% before prediabetes classification begins.

The triglyceride-to-HDL ratio, as noted above, is a strong indirect marker. In mg/dL units, a ratio above 3.0 correlates with insulin resistance. Below 2.0 is optimal. This is particularly useful because it requires no additional testing beyond a standard lipid panel, though it should prompt fasting insulin testing rather than replace it.

Waist circumference measured at the navel provides a practical clinical proxy for visceral adiposity, the fat depot most directly associated with insulin resistance. In men, above 40 inches (102 cm) is considered high risk. In women, above 35 inches (88 cm). Visceral fat drives the hepatic insulin resistance that underpins much of the HOMA-IR elevation seen in metabolic syndrome.

Postprandial glucose measured two hours after a meal complements the fasting picture by revealing how the metabolic system handles a glucose challenge. A 2-hour postprandial glucose below 120 mg/dL is optimal; below 140 mg/dL is the clinical threshold considered normal. Continuous glucose monitoring (CGM) devices, now increasingly available without a prescription, allow this measurement across multiple real-world meals rather than a single clinical test. Our article on CGM in non-diabetics explains how to interpret CGM data alongside static fasting tests.

Inflammatory markers, particularly high-sensitivity C-reactive protein (hs-CRP) and ferritin, frequently co-elevate with insulin resistance and serve as independent cardiovascular risk markers. For a complete overview of what inflammation testing adds to a metabolic panel, see our guide on inflammation markers in blood testing.

If you are new to interpreting blood test results in general, our guide to reading blood test results explains reference ranges, optimal ranges, and how to track trends over time.

What to Do With Your Results

If your HOMA-IR is above 2.5 or your fasting insulin is above 10 uIU/mL with normal glucose, you are in the compensatory window. The interventions with the strongest evidence base for improving insulin sensitivity include reducing dietary refined carbohydrates and ultra-processed foods, increasing resistance training (which drives GLUT4 translocation in skeletal muscle independently of insulin), improving sleep quality (sleep restriction acutely increases fasting insulin within days), and in cases of significant visceral adiposity, achieving modest weight loss of five to ten percent of body weight.

Retesting every three to six months while implementing lifestyle changes allows you to track whether HOMA-IR is moving in the right direction. Beta cells, if not too far depleted, can recover function. Peripheral insulin sensitivity can improve substantially with consistent lifestyle intervention. The window is real, the intervention works, and testing fasting insulin is how you know the window is open before it closes.

The practical takeaway is simple: when ordering blood work for metabolic health, request fasting insulin alongside fasting glucose. Calculate HOMA-IR. Apply optimal rather than laboratory reference thresholds. And treat the combination as a single integrated measure of how hard your metabolic system is working to maintain normal blood sugar, not just whether that blood sugar has crossed a diagnostic line.

Key Sources

• Kraft JR. Detection of Diabetes Mellitus in Situ (Occult Diabetes). Lab Med. 1975;6(2):10-22. -- Screening of 14,384 patients with five-hour glucose and insulin curves; 75% of normal-glucose patients had abnormal insulin responses; insulin patterns predicted cardiovascular disease.
• Matthews DR et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations. Diabetologia. 1985;28(7):412-419. -- Original derivation and validation of the HOMA-IR formula; foundational methodology paper for the field.
• Hu FB et al. Diet, Lifestyle, and the Risk of Type 2 Diabetes Mellitus in Women. N Engl J Med. 2001;345(11):790-798. -- Nurses Health Study; confirmed elevated fasting insulin as independent predictor of type 2 diabetes and cardiovascular disease before glucose rises.
• Tabak AG et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes. Lancet. 2009;373(9682):2215-2221. -- Mapped pre-diagnosis insulin and glucose trajectories in 6,538 civil servants; showed insulin resistance precedes glucose rise by up to 13 years.
• McLaughlin T et al. Use of Metabolic Markers to Identify Overweight Individuals Who Are Insulin Resistant. Ann Intern Med. 2003;139(10):802-809. -- Validated triglyceride-to-HDL ratio as a strong clinical proxy for insulin resistance; ratio above 3.0 in mg/dL strongly predicts elevated HOMA-IR.